Q-omics provides the consensus-scored FCGR2A profile across patient tissues and cancer cell-line models. FCGR2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FCGR2A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FCGR2A RNA expression shows 25,021 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where FCGR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR2A survival associations across molecular data types. FCGR2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR2A RNA expression–survival associations across cancer types. High FCGR2A expression shows unfavorable associations in LGG, LUSC, KIRP, STAD and ACC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FCGR2A RNA expression.
This table summarizes FCGR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FCGR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR2A shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, HNSC, THCA and STAD. The KIRC box plot shows higher FCGR2A RNA expression in tumor versus normal tissue (log2 FC = +2.260, t-test p < 0.001).
This table shows molecular features associated with FCGR2A in patient tissues and cancer cell lines. In patient samples, FCGR2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
